Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | blood | Geigy Scientific Tables, 8th Rev edition. Edited by C. Lentner, West Cadwell, N.J.: Medical education Div., Ciba-Geigy Corp., Basel, Switzerland c1981-1992. | ||
NPO20338 | Mus musculus | Species | Muridae | Eukaryota |
PMID[19425150] |
|||
NPO730 | Escherichia coli | Species | Enterobacteriaceae | Bacteria |
PMID[21988831] |
|||
NPO29604 | Lasiosphaera seu calvatia | NA | NA | NA | TCMSP* |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | > | 100000 | nM | 12213051 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | > | 100000 | nM | 12213051 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 300 | nM | 12213051 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 15 | nM | 11754592 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | > | 10000 | nM | 11206448 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 100 | nM | 11206448 |
NPT2672 | Individual Protein | Dihydroorotase | Homo sapiens | Activity | = | 54 | % | 10.1016/0960-894X(96)00452-0 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 86 | nM | 16366591 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 13 | nM | 16942026 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 42 | nM | 17125260 |
NPT4962 | Individual Protein | Pyrimidinergic receptor P2Y6 | Rattus norvegicus | EC50 | = | 200 | nM | 18760862 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 300 | nM | 18514530 |
NPT2 | Others | Unspecified | Inhibition | = | 22 | % | 19119008 | |
NPT2 | Others | Unspecified | Kd | = | 14000 | nM | 19119008 | |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 530 | nM | 19902968 |
NPT4712 | Individual Protein | Purinergic receptor P2Y14 | Homo sapiens | EC50 | = | 160 | nM | 19902968 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 140 | nM | 20095577 |
NPT909 | Individual Protein | Seminal ribonuclease | Bos taurus | Ki | = | 1046400 | nM | 19643512 |
NPT908 | Individual Protein | Ribonuclease pancreatic | Bos taurus | Ki | = | 647000 | nM | 19643512 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 300 | nM | 20446735 |
NPT4712 | Individual Protein | Purinergic receptor P2Y14 | Homo sapiens | EC50 | = | 160 | nM | 20446735 |
NPT5696 | Individual Protein | UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit | Homo sapiens | IC50 | = | 1800 | nM | 21273069 |
NPT62 | Individual Protein | 6-phospho-1-fructokinase | Trypanosoma brucei | Potency | 849.2 | nM | PubChem BioAssay data set | |
NPT64 | Individual Protein | ATPase family AAA domain-containing protein 5 | Homo sapiens | Potency | 29081 | nM | PubChem BioAssay data set | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 16500 | nM | 21417463 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 14000 | nM | 21417463 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 48 | nM | 21417463 |
NPT7 | Individual Protein | Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus | Potency | 316.2 | nM | PubChem BioAssay data set | |
NPT4962 | Individual Protein | Pyrimidinergic receptor P2Y6 | Rattus norvegicus | EC50 | = | 200 | nM | 22107038 |
NPT2 | Others | Unspecified | IC50 | = | 46000 | nM | 22356319 | |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 150 | nM | 22901672 |
NPT4503 | Individual Protein | Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 | Homo sapiens | Activity | = | 50 | % | 22901672 |
NPT4507 | Individual Protein | Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 | Homo sapiens | Activity | = | 45 | % | 22901672 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 47 | nM | 22901672 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 15 | nM | 22901672 |
NPT2 | Others | Unspecified | EC50 | = | 500 | nM | 22901672 | |
NPT2 | Others | Unspecified | Ki | = | 650000 | nM | 23122937 | |
NPT4712 | Individual Protein | Purinergic receptor P2Y14 | Homo sapiens | EC50 | = | 160000 | nM | 25868749 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC283698 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC73765 |
0.9885 | High Similarity | NPC36985 |
0.9885 | High Similarity | NPC17892 |
0.9655 | High Similarity | NPC320249 |
0.9655 | High Similarity | NPC322594 |
0.954 | High Similarity | NPC324390 |
0.9121 | High Similarity | NPC317639 |
0.908 | High Similarity | NPC43246 |
0.908 | High Similarity | NPC89051 |
0.8969 | High Similarity | NPC329277 |
0.8788 | High Similarity | NPC149843 |
0.8788 | High Similarity | NPC155087 |
0.8736 | High Similarity | NPC106780 |
0.8602 | High Similarity | NPC324516 |
0.8602 | High Similarity | NPC318166 |
0.8587 | High Similarity | NPC327344 |
0.837 | Intermediate Similarity | NPC315063 |
0.8229 | Intermediate Similarity | NPC120887 |
0.8152 | Intermediate Similarity | NPC163352 |
0.8152 | Intermediate Similarity | NPC210456 |
0.8144 | Intermediate Similarity | NPC328779 |
0.8125 | Intermediate Similarity | NPC226769 |
0.8125 | Intermediate Similarity | NPC280946 |
0.8125 | Intermediate Similarity | NPC6166 |
0.798 | Intermediate Similarity | NPC328914 |
0.7857 | Intermediate Similarity | NPC90240 |
0.7835 | Intermediate Similarity | NPC329384 |
0.7826 | Intermediate Similarity | NPC71339 |
0.7826 | Intermediate Similarity | NPC112842 |
0.7742 | Intermediate Similarity | NPC325723 |
0.764 | Intermediate Similarity | NPC329077 |
0.7632 | Intermediate Similarity | NPC284651 |
0.7423 | Intermediate Similarity | NPC171116 |
0.7396 | Intermediate Similarity | NPC190334 |
0.7396 | Intermediate Similarity | NPC62927 |
0.7083 | Intermediate Similarity | NPC229249 |
0.6989 | Remote Similarity | NPC325902 |
0.6634 | Remote Similarity | NPC328806 |
0.6557 | Remote Similarity | NPC315058 |
0.6531 | Remote Similarity | NPC319753 |
0.64 | Remote Similarity | NPC313962 |
0.6383 | Remote Similarity | NPC315806 |
0.625 | Remote Similarity | NPC109188 |
0.6239 | Remote Similarity | NPC478024 |
0.6129 | Remote Similarity | NPC325750 |
0.6077 | Remote Similarity | NPC318142 |
0.5691 | Remote Similarity | NPC313813 |
0.56 | Remote Similarity | NPC470782 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC283698 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
1.0 | High Similarity | NPD9639 | Clinical (unspecified phase) |
0.908 | High Similarity | NPD9581 | Clinical (unspecified phase) |
0.908 | High Similarity | NPD9580 | Clinical (unspecified phase) |
0.8969 | High Similarity | NPD3129 | Phase 3 |
0.8866 | High Similarity | NPD3128 | Phase 3 |
0.8539 | High Similarity | NPD9557 | Clinical (unspecified phase) |
0.8208 | Intermediate Similarity | NPD3139 | Phase 3 |
0.8113 | Intermediate Similarity | NPD3138 | Phase 3 |
0.8105 | Intermediate Similarity | NPD1686 | Approved |
0.809 | Intermediate Similarity | NPD9556 | Approved |
0.8085 | Intermediate Similarity | NPD9565 | Discontinued |
0.8061 | Intermediate Similarity | NPD5789 | Clinical (unspecified phase) |
0.8 | Intermediate Similarity | NPD9561 | Approved |
0.8 | Intermediate Similarity | NPD9560 | Approved |
0.798 | Intermediate Similarity | NPD1455 | Phase 3 |
0.798 | Intermediate Similarity | NPD1454 | Phase 3 |
0.7979 | Intermediate Similarity | NPD755 | Phase 3 |
0.7912 | Intermediate Similarity | NPD9546 | Phase 2 |
0.7889 | Intermediate Similarity | NPD9558 | Phase 3 |
0.7826 | Intermediate Similarity | NPD280 | Approved |
0.7826 | Intermediate Similarity | NPD9533 | Phase 2 |
0.7778 | Intermediate Similarity | NPD502 | Approved |
0.7766 | Intermediate Similarity | NPD241 | Discontinued |
0.766 | Intermediate Similarity | NPD9562 | Discovery |
0.766 | Intermediate Similarity | NPD240 | Phase 3 |
0.766 | Intermediate Similarity | NPD170 | Approved |
0.7593 | Intermediate Similarity | NPD7914 | Suspended |
0.7527 | Intermediate Similarity | NPD9559 | Phase 1 |
0.7527 | Intermediate Similarity | NPD9529 | Phase 1 |
0.7475 | Intermediate Similarity | NPD501 | Phase 1 |
0.7447 | Intermediate Similarity | NPD238 | Clinical (unspecified phase) |
0.7447 | Intermediate Similarity | NPD239 | Phase 2 |
0.7429 | Intermediate Similarity | NPD6946 | Approved |
0.7423 | Intermediate Similarity | NPD841 | Approved |
0.7396 | Intermediate Similarity | NPD9604 | Approved |
0.7396 | Intermediate Similarity | NPD9603 | Phase 3 |
0.7396 | Intermediate Similarity | NPD9602 | Phase 3 |
0.7327 | Intermediate Similarity | NPD762 | Discontinued |
0.7273 | Intermediate Similarity | NPD251 | Approved |
0.7238 | Intermediate Similarity | NPD1061 | Clinical (unspecified phase) |
0.71 | Intermediate Similarity | NPD6943 | Clinical (unspecified phase) |
0.71 | Intermediate Similarity | NPD9585 | Discontinued |
0.7083 | Intermediate Similarity | NPD9601 | Approved |
0.7041 | Intermediate Similarity | NPD1760 | Approved |
0.6957 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.6952 | Remote Similarity | NPD223 | Clinical (unspecified phase) |
0.6881 | Remote Similarity | NPD1385 | Discontinued |
0.6827 | Remote Similarity | NPD514 | Clinical (unspecified phase) |
0.6822 | Remote Similarity | NPD7651 | Approved |
0.68 | Remote Similarity | NPD301 | Discontinued |
0.68 | Remote Similarity | NPD9553 | Approved |
0.68 | Remote Similarity | NPD9554 | Approved |
0.6797 | Remote Similarity | NPD7761 | Suspended |
0.6771 | Remote Similarity | NPD9600 | Approved |
0.6699 | Remote Similarity | NPD279 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD267 | Discontinued |
0.6633 | Remote Similarity | NPD9572 | Clinical (unspecified phase) |
0.6581 | Remote Similarity | NPD7992 | Clinical (unspecified phase) |
0.6542 | Remote Similarity | NPD192 | Phase 2 |
0.6531 | Remote Similarity | NPD9573 | Phase 2 |
0.6505 | Remote Similarity | NPD500 | Discontinued |
0.6476 | Remote Similarity | NPD215 | Discontinued |
0.6383 | Remote Similarity | NPD9653 | Clinical (unspecified phase) |
0.6337 | Remote Similarity | NPD9555 | Phase 2 |
0.6327 | Remote Similarity | NPD9429 | Discontinued |
0.6292 | Remote Similarity | NPD9503 | Approved |
0.6292 | Remote Similarity | NPD9504 | Approved |
0.6262 | Remote Similarity | NPD6948 | Phase 3 |
0.625 | Remote Similarity | NPD9407 | Approved |
0.625 | Remote Similarity | NPD2633 | Phase 1 |
0.625 | Remote Similarity | NPD4743 | Phase 2 |
0.625 | Remote Similarity | NPD1331 | Approved |
0.6224 | Remote Similarity | NPD9427 | Approved |
0.6207 | Remote Similarity | NPD1805 | Phase 2 |
0.6207 | Remote Similarity | NPD1804 | Phase 2 |
0.614 | Remote Similarity | NPD1428 | Phase 2 |
0.6121 | Remote Similarity | NPD284 | Phase 1 |
0.604 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.6034 | Remote Similarity | NPD6693 | Phase 3 |
0.5946 | Remote Similarity | NPD3121 | Phase 2 |
0.5938 | Remote Similarity | NPD9405 | Approved |
0.5922 | Remote Similarity | NPD205 | Approved |
0.5902 | Remote Similarity | NPD6935 | Phase 3 |
0.5902 | Remote Similarity | NPD6936 | Clinical (unspecified phase) |
0.59 | Remote Similarity | NPD9403 | Discontinued |
0.5893 | Remote Similarity | NPD765 | Discontinued |
0.5833 | Remote Similarity | NPD285 | Discontinued |
0.5739 | Remote Similarity | NPD244 | Clinical (unspecified phase) |
0.5727 | Remote Similarity | NPD1706 | Clinical (unspecified phase) |
PubChem CID   | 6031 |
ChEMBL   | CHEMBL130266 |
ZINC   |
Molecular Weight:   | 404.00 |
ALogP:   | -2.7621 |
MLogP:   | 0.69 |
XLogP:   | -4.669 |
# Rotatable Bonds:   | 12 |
Polar Surface Area:   | 235.5 |
# H-Bond Aceptor:   | 14 |
# H-Bond Donor:   | 6 |
# Rings:   | 2 |
# Heavy Atoms:   | 25 |